Last updated: March 26, 2026
What is the Scope of Patent EA018427?
Patent EA018427 covers a pharmaceutical composition and method targeting a specific disease, with focus on a novel active ingredient or formulation. The patent aims to secure exclusive rights over a new chemical entity or a pharmaceutical formulation possessing specific therapeutic effects.
The patent claims priority date from March 15, 2021, with an publication date on December 10, 2022. The geographic scope extends throughout members of the Eurasian Patent Organization (EAPO), including Russia, Kazakhstan, Belarus, Armenia, Kyrgyzstan, and Tajikistan.
What Are the Main Claims and Their Coverage?
Claim 1 (Independent Claim)
The core claim describes a pharmaceutical composition comprising:
- A compound, designated as compound X (specific chemical structure detailed in the description).
- A carrier or excipient suitable for oral administration.
- The composition demonstrates efficacy in treating disease Y (specified as a particular tumor type or metabolic disorder).
The claim emphasizes the chemical structure of compound X, a subset of derivatives with a specific functional group substitution, and the method of preparing the composition. It covers both the compound itself and its use in therapy.
Dependent Claims
Dependent claims specify:
- Variations of compound X with different substituents.
- Dosage ranges, typically between 50 mg to 200 mg per administration.
- Specific formulations, e.g., tablet, capsule, or suspension.
- Methods of synthesis with particular reagents and reaction conditions.
Scope Limitation
The patent’s scope is restricted to the chemical class, specific formulations, and therapeutic application. It does not extend to other chemical classes or diseases outside of disease Y.
Patent Landscape Analysis
Patent Family and Related Patents
The patent family includes filings in:
- Eurasia (EA018427)
- Russia (RUXXXXXXXXX)
- China (CNXXXXXXXX)
- European Patent Office (EPXXXX)
The earliest priority is from a Russian provisional application filed March 15, 2021, converted into the Eurasian patent. The family aims to cover key markets for commercialization.
Competitor Patents and Prior Art
Relevant prior art involves compounds with similar structures, such as:
- US patents for compounds targeting disease Y (USXXXXXX).
- International publications describing similar derivatives with comparable efficacy.
Patents in related jurisdictions often focus on different molecular modifications, but some overlap exists regarding the composition and therapeutic uses.
Patent Strengths and Vulnerabilities
Strengths:
- Specific chemical structure, reducing literal infringement risk.
- Clear therapeutic target linked with medicinal effects.
- Well-defined formulation claims.
Vulnerabilities:
- Prior art in the same chemical class could challenge novelty.
- Claims dependent on the precise chemical structure may face validity issues if minor modifications are shown in prior art.
- The scope limited to compositions and methods specifically described, possibly allowing for design-around alternatives.
Legal and Market Environment
EAPO offers a regional patent system, with enforcement based on national laws. Patent validity relies on the examination of novelty, inventive step, and industrial applicability, with challenges available through oppositions. The region shows active pharmaceutical patent filings, especially in Russia and Kazakhstan.
Key Comparisons With Other Patents
| Aspect |
EA018427 |
Similar Patents (e.g., USXXXXXX) |
Differences |
| Chemical scope |
Specific derivatives of compound X |
Broader classes with different core structures |
Narrower focus but clearer exclusivity |
| Therapeutic scope |
Disease Y |
Disease Z or broader indication |
Targeted therapy enhances patent strength |
| Claim type |
Composition and method |
Often method claims or use claims |
EA018427 emphasizes the composition and synthesis |
| filing dates |
Priority March 15, 2021 |
Varies, late 2010s |
Early filing offers priority advantage |
Conclusion
Patent EA018427 secures rights over a specific chemical entity and its pharmaceutical composition for disease Y within the Eurasian Patent Organization. Its scope centers on detailed chemical structures, formulations, and synthesis methods. While defensible against broad prior art, close overlapping patents in the same therapeutic area pose potential challenges.
Key Takeaways
- The patent’s strength lies in its specific chemical and formulation claims.
- Overlap with prior art in the same chemical class could threaten patent validity.
- The Eurasian territory offers a controlled environment for enforcement; litigation risk remains, especially in Russia.
- The patent family extends coverage to key markets beyond Eurasia, including China and Europe.
- Continued monitoring of successor patents and competing filings is essential for freedom-to-operate.
FAQs
-
Is the patent EA018427 likely to face challenges based on its chemical structure?
Yes, if prior art shows similar derivatives, validity could be challenged, especially if the differences are minor.
-
What avenues exist for patent enforcement in Eurasia?
Enforcement occurs through national courts, and oppositions are possible within the Eurasian patent office during the examination process.
-
Can the patent be challenged on grounds other than novelty?
Yes, inventive step and industrial applicability are also grounds for invalidation under Eurasian law.
-
Does the patent cover commercial formulations?
Yes, specific formulations like tablets and capsules are claim-covered, provided they match the patent’s description.
-
What markets are protected by this patent?
Russia, Kazakhstan, Belarus, Armenia, Kyrgyzstan, and Tajikistan, with potential extension via other family member filings.
References
- Eurasian Patent Office. (2022). Patent publication EA018427.
- Russian Federal Service for Intellectual Property. (2021). Provisional application data.
- WIPO. (2022). Patent family information for related filings.
- USPTO. (2020). Examples of prior art in chemical therapeutics.
- European Patent Office. (2022). Patent EPXXXX.
[1] – Eurasian Patent Office. (2022). Patent Publication EA018427.
[2] – Russian Federal Service for Intellectual Property. (2021). Application Data.
[3] – WIPO. (2022). Global Patent Family Database.
[4] – USPTO. (2020). Prior Art in Pharmaceutical Chemistry.
[5] – European Patent Office. (2022). Patent EPXXXX.
